Molecular ‘calcium sponge’ to tackle HF

Researchers have utilised molecular genetic engineering to optimize heart performance in models of diastolic heart failure by creating an optimized protein that can aid in high-speed relaxation similar to fast twitching muscles.

Within heart cells, calcium plays a major role in orchestrating normal heart pump function. However, in diastolic failure the calcium signalling process is slowed; calcium levels rise to the peak needed for the squeezing action of the heart but don’t then drop quickly enough for an efficient relaxation period – the condition known as diastolic heart failure.

University researchers were able to pinpoint a specific protein, parvalbumin – which aids in high-speed relaxation of fast twitching muscles in nature – and optimize it to become a calcium sponge for heart muscle. As a result, the optimized protein, ParvE101Q, soaks up excess calcium at a precise instant, allowing the heart to relax efficiently after contraction.

The advance offers a solid conceptual step forward in solving the puzzle of diastolic heart failure. The next step will be determining the best possible small molecule or gene delivery mechanism for the protein, which should allow the discovery to be used in clinics.

Their approach is outlined in the latest issue of Nature Medicine.

“In nature, there are unique organisms known to be able to contract and relax muscles quickly,” said Joseph M. Metzger, Ph.D., a University of Minnesota Medical School professor and chair of the Department of Integrative Biology and Physiology. “We hoped research and discovery could help identify what was promoting this highly efficient activity so we could harness it for use in the heart. We’ve discovered that our optimized variation of parvalbumin can fulfil that role by treating diastolic heart failure.”

According to Metzger, who also serves as the Maurice B. Visscher Endowed Chair in Physiology, the sponge mechanism works as a temporary depot for calcium along its normal pathway. It increases productivity in the relaxation phase of the heart cycle without negatively impacting the contracting phase.

If they can develop an ideal delivery system for the optimized protein, the researchers believe they may have found a unique clinical application to treat diastolic heart failure. Heart failure is a common killer of both men and women across the country and the rate of heart failure is increasing as our population ages and as the survival rate after recovery from first heart attack goes up.

“Heart disease and heart failure rates are growing, especially as our population ages. We hope this type of discovery may one day help pave the way to a better way to treat patients,” said Metzger.

Collaborating with University of Minnesota investigators were researchers from the University of Miami (FL) Leonard M. Miller School of Medicine and The Ohio State University College of Medicine.

Funding for this project was provided in part by the National Institutes of Health via grants HL115876, HL59301, HL71016. Researchers also received support from the American Heart Association, the Lillehei Heart Institute, the University of Minnesota Medical School and the Visscher Endowed Chair.

For further information contact: Caroline Marin  crmarin@umn.edu